VTAK — Catheter Precision Income Statement
0.000.00%
Last trade - 00:00
- $4.54m
- $1.16m
- $0.44m
- 23
- 35
- 25
- 17
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.27 | 0.259 | 0.022 | 0.014 | 0.442 |
Cost of Revenue | |||||
Gross Profit | -2.86 | -1.91 | -1.54 | -0.147 | 0.412 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 53.9 | 35.7 | 27.3 | 27 | 78.6 |
Operating Profit | -52.6 | -35.4 | -27.2 | -27 | -78.1 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -51.6 | -35.3 | -27.3 | -26.9 | -70.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | -51.7 | -35.3 | -27.3 | -26.9 | -70.6 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -57 | -36 | -25.1 | -26.9 | -70.6 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -57 | -36 | -25.1 | -26.9 | -71.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -4,910 | -1,039 | -283 | -23.4 | -1.9 |